Valerio Therapeutics S.A. (ALVIO) is a Biotechnology company in the Healthcare sector, listed on Euronext Paris. This page provides the complete earnings calendar, dividend schedule, and financial data for Valerio Therapeutics S.A. in 2026. The next earnings report is expected on September 2, 2026.
Next earnings date
02 Sep 2026
In 12 days
EPS estimate
—
Revenue estimate
—
Past earnings
Latest earnings analysis
Consensus estimates were not available to assess Valerio Therapeutics S.A.'s performance, with EPS of USD -0.1153 and revenue of USD 0. No previous report data is available for comparison.
No dividend history available.
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Valerio Therapeutics S.A. (ALVIO) is scheduled to report earnings on September 2, 2026.
Valerio Therapeutics S.A. (ALVIO) last reported earnings on September 13, 2022.
Valerio Therapeutics S.A. (ALVIO) is listed on Euronext Paris.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.